Literature DB >> 15578883

Salivary adenocarcinoma, not otherwise specified: a collection of orphans.

Jiang Li1, Beverly Yiyao Wang, Magalie Nelson, Lei Li, Yuhua Hu, Mark L Urken, Margaret Brandwein-Gensler.   

Abstract

CONTEXT: Salivary adenocarcinoma, not otherwise specified, refers to gland-forming malignancies that do not satisfy the diagnostic requirements of other "named" malignancies.
OBJECTIVE: To review the features of 11 patients with salivary adenocarcinoma, not otherwise specified. To also compare the diagnostic frequencies of 2 databases, one from the Mount Sinai Medical Center (New York, NY), the other from the Shanghai Ninth People's Hospital (Shanghai, People's Republic of China).
DESIGN: Pathology files were searched to establish a database of salivary tumors. All available hematoxylin-eosin- stained slides from the resection specimens diagnosed as either adenocarcinoma, not otherwise specified, or with vague or unusual diagnoses (eg, probable carcinoma-ex-pleomorphic adenoma) were pulled from our files and reexamined. Dates of death were confirmed with the Social Security Death Index.
RESULTS: We identified 11 patients with salivary adenocarcinoma, not otherwise specified, ranging in age from 49 to 80 years (median, 67 years), with a male preponderance. The parotid gland was the most common site of tumor origin. Ten of these tumors were high grade, and 1 was intermediate grade. Two patients were diagnosed at stage II, while the remaining patients were diagnosed at stage III or IV. Histologically, all tumors were invasive, with variable glandular differentiation and diverse architectural patterns. The diverse cytologic tumor cell types included cuboidal, columnar, epithelioid, polygonal, oncocytoid, clear, melanoma-like, mucinous, sebaceous, and plasmacytoid. Four patients died after 4 to 27 months (mean, 15 months), 1 patient is alive with disease at 12 months, 1 patient is disease-free at 14 years, and 3 patients remain disease-free after short follow-ups (10, 12, and 12 months). One patient had surgery just recently, and the remaining patient had no follow-up.
CONCLUSIONS: Salivary adenocarcinoma, not otherwise specified, is an aggressive, high-grade malignancy, with a predisposition for the parotid gland. It is characterized by cytologic and architectural diversity and an invasive growth pattern.

Entities:  

Mesh:

Year:  2004        PMID: 15578883     DOI: 10.5858/2004-128-1385-SANOSA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

1.  Intraoral Pigmented Low-Grade Adenocarcinoma, Not Otherwise Specified: Case Report and Immunohistochemical Study.

Authors:  Jessica Luana Dos Santos; Albina Messias de Almeida Milani Altemani; Alexandre Elias Trivellato; Cássio Edvard Sverzut; Luciana Yamamoto Almeida; Lucas Ribeiro Teixeira; Alfredo Ribeiro-Silva; Jorge Esquiche León
Journal:  Head Neck Pathol       Date:  2017-12-22

2.  My journey into the world of salivary gland sebaceous neoplasms.

Authors:  Douglas R Gnepp
Journal:  Head Neck Pathol       Date:  2012-03-20

Review 3.  Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature.

Authors:  Wenyi Luo; Sarah W Lindley; Peter H Lindley; Gregory A Krempl; Raja R Seethala; Kar-Ming Fung
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  Mucinous adenocarcinoma of minor salivary glands: a high-grade malignancy prone to lymph node metastasis.

Authors:  Fumio Ide; Kenji Mishima; Akio Tanaka; Ichiro Saito; Kaoru Kusama
Journal:  Virchows Arch       Date:  2008-11-27       Impact factor: 4.064

5.  [Epidemiological profile of primary malignant tumors of the salivary glands: about 154 cases].

Authors:  Khadija Setti; Mohamed Mouanis; Abdelmounim Moumni; Mostafa Maher; Amal Harmouch
Journal:  Pan Afr Med J       Date:  2014-02-18

6.  Establishment and Validation of Prognostic Nomograms for Patients With Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 to 2016.

Authors:  Zi-Meng Wang; Zuo-Lin Xiang
Journal:  Front Surg       Date:  2022-01-11

7.  Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes.

Authors:  He-Ming Wu; Guo-Xin Ren; Li-Zhen Wang; Chun-Ye Zhang; Wan-Tao Chen; Wei Guo
Journal:  Mol Med Rep       Date:  2012-05-09       Impact factor: 2.952

8.  The buccal minor salivary glands as starting point for a metastasizing adenocarcinoma--report of a case.

Authors:  Tobias Ettl; Johannes Kleinheinz; Ravi Mehrotra; Stephan Schwarz; Torsten Eugen Reichert; Oliver Driemel
Journal:  Head Face Med       Date:  2008-07-30       Impact factor: 2.151

9.  RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.

Authors:  Chun-Ye Zhang; Yang-Xing Zhao; Rong-Hui Xia; Jing Han; Bing-Shun Wang; Zhen Tian; Li-Zhen Wang; Yu-Hua Hu; Jiang Li
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

Review 10.  Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.

Authors:  Larissa Di Villeneuve; Ive Lima Souza; Fernanda Davila Sampaio Tolentino; Renata Ferrarotto; Gustavo Schvartsman
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.